1.27

4.51% -0.06

After Hours: 1.27

Pulmonx Corp (LUNG)

Overview News Price History Option Chain Financials Discussions Forecast

Pulmonx Corp stock is traded at $1.27, with a volume of 716.95K. It is down -4.51% in the last 24 hours and down -4.51% over the past month. Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Previous Close:

$1.33

Open:

$1.34

24h Volume:

716.95K

Relative Volume:

1.35

Market Cap:

$53.64M

Revenue:

$88.55M

Net Income/Loss:

$-53.21M

P/E Ratio:

-0.9815

EPS:

-1.2939

Net Cash Flow:

$-32.90M

1W Performance:

+3.25%

1M Performance:

-4.51%

6M Performance:

-25.29%

1Y Performance:

-64.53%

1-Day Range:

$1.24

$1.35

1-Week Range:

$1.18

$1.45

52-Week Range:

$1.13

$3.88

Pulmonx Corp Stock (LUNG) Company Profile

Name

Pulmonx Corp

Sector

Healthcare (1106)

Industry

Medical Devices (142)

Phone

650-364-0400

Address

700 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

296

Twitter

Next Earnings Date

2026-04-29

Latest SEC Filings

LUNG's Discussions on Twitter

Compare LUNG vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LUNG Pulmonx Corp	1.27	56.18M	88.55M	-53.21M	-32.90M	-1.2939
ABT Abbott Laboratories	87.17	152.48B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	295.25	111.40B	25.27B	3.34B	4.57B	8.6358
MDT Medtronic Plc	77.79	100.53B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	55.98	84.50B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	82.91	48.04B	6.30B	1.07B	1.34B	1.8406

Pulmonx Corp Stock (LUNG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-31-25	Downgrade	Piper Sandler	Overweight → Neutral
Mar-10-25	Initiated	D. Boral Capital	Buy
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Jun-04-24	Initiated	Lake Street	Buy
Feb-23-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-05-23	Initiated	Craig Hallum	Buy
Feb-27-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-03-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Jul-11-22	Downgrade	Citigroup	Buy → Neutral
Mar-02-22	Resumed	BofA Securities	Neutral
Dec-08-21	Upgrade	Piper Sandler	Neutral → Overweight
Apr-01-21	Initiated	Citigroup	Buy
Mar-25-21	Initiated	Piper Sandler	Neutral
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jan-04-21	Downgrade	BofA Securities	Buy → Neutral
Oct-26-20	Initiated	BofA Securities	Buy
Oct-26-20	Initiated	Canaccord Genuity	Buy
Oct-26-20	Initiated	Morgan Stanley	Equal-Weight
Oct-26-20	Initiated	Stifel	Buy
Oct-26-20	Initiated	Wells Fargo	Equal Weight

View All

Pulmonx Corp Stock (LUNG) Latest News

07:20 AM

Pulmonx Corporation Q1 2026 Financial Report Highlights, Forward-Looking Statements, and Key Risk Factors - Minichart

07:20 AM

May 04, 2026

Pulmonx (NASDAQ: LUNG) secures $40M Perceptive loan and ends Q1 with $61.6M cash - Stock Titan

May 04, 2026

Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary - TradingView

May 04, 2026

May 02, 2026

Pulmonx (NASDAQ:LUNG) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

May 02, 2026

Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

May 02, 2026

May 01, 2026